Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML.
about
Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapyMyelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and managementClinical and genetic predictors of prognosis in myelodysplastic syndromes.The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemiaClonal evolution in myelodysplastic syndromesPhase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progressionDetectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomesMolecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.Genetic stratification in myeloid diseases: from risk assessment to clinical decision support tool.Natural history of chronic myelomonocytic leukemia: gene sequencing identifies multiple clonal molecular abnormalities associated with rapid progression to acute myeloid leukemiaKaryotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia.Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes.
P2860
Q26749870-5FB47086-369C-4CCF-AE10-F401C423B476Q26796240-DC193A2E-E438-4DC4-9180-7EA03AA75B28Q33695906-1E1E09C1-55CE-4803-88E0-E24D4094C513Q33796552-6196EEAB-624E-4BFA-943D-9964544E82B4Q34555597-4C45BE3D-2880-4B25-8ACD-6FF099B50436Q35872060-05423452-3032-462E-AD87-B2B7016C910AQ36522731-1BD5E988-2E56-4961-B28C-DC71D03845C0Q36770211-E0DC05D2-F3F7-4398-BE43-3AE91E8D9C19Q38415206-E593E971-C8CD-46FD-B549-3B111CA30033Q38905610-A2F8AF61-612B-425E-80BA-3014717A5361Q39100115-EDFA9EE6-5C5F-48C3-8137-230D59B44AE8Q42157464-B43F5BE8-5850-40CB-900A-6DBB3AF1506AQ43146967-F02F7BA0-22F4-4E09-BA3F-9C71EF79F306Q47548041-E6BA2A13-4442-4B0A-87A0-6DEFC361676BQ49533848-2BDC12CA-0A92-4967-8808-A224F5599747
P2860
Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Dynamic acquisition of FLT3 or ...... wer risk MDS to secondary AML.
@en
Dynamic acquisition of FLT3 or ...... wer risk MDS to secondary AML.
@nl
type
label
Dynamic acquisition of FLT3 or ...... wer risk MDS to secondary AML.
@en
Dynamic acquisition of FLT3 or ...... wer risk MDS to secondary AML.
@nl
prefLabel
Dynamic acquisition of FLT3 or ...... wer risk MDS to secondary AML.
@en
Dynamic acquisition of FLT3 or ...... wer risk MDS to secondary AML.
@nl
P2093
P2860
P356
P1433
P1476
Dynamic acquisition of FLT3 or ...... wer risk MDS to secondary AML.
@en
P2093
C Bueso-Ramos
G Garcia-Manero
H Kantarjian
K Takahashi
P2860
P2888
P304
P356
10.1038/LEU.2013.165
P577
2013-06-07T00:00:00Z